Buprenorphine for the management of acute pain
Buprenorphine was first used for the management of postoperative pain in the mid-1970s, with the earliest study comparing the drug to a pure opioid agonist (morphine) published in 1977 1 . It was initially available for use by intramuscular (IM) or intravenous (IV) injection, but studies using a sublingual (SL) tablet of buprenorphine followed soon after. These preparations were first listed on the Australian Register of Therapeutic Goods in 1991 2 (it was available for use before then) and the injectable form was approved for registration in New Zealand in 1979 3 , although administration by either route did not become common clinical practice in the management of acute pain in humans. However, over recent years, there has been a small resurgence in interest in the use of buprenorphine for the management of acute postoperative pain using IV 4 and SL 5, 6 formulations of the drug as well as buprenorphine transdermal patches [6] [7] [8] .
Buprenorphine is derived from thebaine, an alkaloid of opium. It is often classed as a partial agonist at the muopioid receptor and an antagonist at the kappa-opioid receptor 9 . Initial suggestions of a ceiling effect for analgesia in humans have been disproved and it should be considered a full opioid agonist for analgesia 1 . Consistent with its partial agonist activity, an apparent ceiling effect for opioid-induced ventilatory impairment (OIVI; opioid-induced respiratory depression) has been demonstrated 10, 11 . Whether this ceiling effect for OIVI extends beyond the dose range tested in the laboratory setting in healthy volunteers, to the high doses potentially used for acute pain management, or is maintained in the setting of co-administered sedatives, is untested.
This issue of the journal includes a very interesting and detailed report of six patients who developed OIVI and a reduction in their level of consciousness following the administration of buprenorphine for management of their pain 6 . Five patients were given SL buprenorphine only, and the sixth patient was also given a transdermal buprenorphine patch, started one hour after surgery, and buprenorphine administered through a femoral nerve catheter in conjunction with a local anaesthetic at the time of surgery. Five of the patients had acute pain and one was treated for pain resulting from post-herpetic neuralgia.
The risk of OIVI from buprenorphine is low compared with the risk from pure agonist opioids such as morphine and fentanyl 12 . In the addiction medicine setting, where much higher doses are used, buprenorphine has been reported to have a much lower overdose death rate compared with methadone when prescribed for the treatment of opioid dependence. However, the risk is not zero, with 0.022 deaths per 1000 prescriptions of buprenorphine compared with 0.137 per 1000 with methadone reported in England and Wales between 2007 and 2012 13 . That is, buprenorphine can lead to significant OIVI in some patients. Richards et al 6 use their cases to provide a well-written and very timely reminder of the potential risks associated with an opioid that has often been assumed to be 'safer' than other opioids. They highlight the fact that "while buprenorphine has … a ceiling effect in relation to respiratory depression in healthy volunteers, it remains an important side-effect", and that the ceiling effect "should not be interpreted as 'no effect'". They also note that the results from a study in young healthy volunteers comparing the respiratory effects of IV fentanyl and buprenorphine showed that fentanyl produces a dosedependent depression of minute ventilation which can lead to apnoea, whereas the depression of minute ventilation after buprenorphine administration, while dose-dependent up to 3 µg/kg, plateaued at higher doses (tested only up to 9 µg/kg) at about 50% of baseline 10 . Susceptible patients, such as the elderly, may tolerate this less well than fitter and younger patients. A reduction of 50% in minute ventilation, however, is likely to be clinically significant and may lead to a progressive rise in PaCO 2 in any patient.
The authors 6 also draw attention to some of the factors that might place patients at increased risk of OIVI when buprenorphine is used. Their list includes advanced age, pre-existing comorbidities, reduced respiratory reserve and co-administration of other central nervous system depressants, including other opioids and non-opioid drugs that may have sedative effects such as pregabalin and clonidine. They also provide an interesting discussion about the possible role of reduced P-glycoprotein (P-gp) in older patients, which could lead to accumulation of the active metabolite norbuprenorphine in the brain, and the possible effects of polymorphisms of ABCB1, the gene encoding for P-gp. Unfortunately, as yet, these latter two factors cannot be routinely identified in all patients.
While the other factors (that is, excluding the roles of P-gp and gene polymorphisms) are often said to increase the risk of OIVI, it is interesting to note that two recent publications have shown that many patients who develop OIVI when given opioids for treatment of their acute pain may not be those who would usually be identified as being 'at risk' 14, 15 . In a closed claims analysis, Lee et al 15 identified 92 claims related to postoperative OIVI over a 20-year period, 77% of which ended in death or severe brain damage. Over half the patients were under the age of 50 years, nearly two-thirds had been assessed as American Society of Anesthesiologists physical status 1 or 2, and less than 10% had a formal diagnosis of obstructive sleep apnoea. A review of 105 reports of OIVI in patients with acute pain also concluded that the "majority of patients had no underlying comorbidities that placed them at increased risk" of OIVI 14 . Overdyk et al 14 estimated that only 30%-40% of the patients included in their review had a comorbidity that could potentially increase their risk of OIVI, including sleepdisordered breathing, renal impairment, and respiratory or neurological disorders. They specifically noted that advanced age was not associated with an increased risk.
Even though there have been no similar large reports looking at OIVI following administration of buprenorphine, it may be reasonable to suggest that even some younger and fitter patients may develop OIVI after its administration, especially if other risk factors as described by Lee et al 15 , including administration of opioids by more than one route (47% of their 92 cases) and co-administration of sedative drugs (34% of cases), are present. Of the six patients in the report by Richards et al 6 , four were given another opioid in addition to buprenorphine (three received oxycodone and one codeine) and one was given midazolam in the operating room the day before. Drugs with sedative sideeffects, including pregabalin 16 and gabapentin, have also been reported to increase the risk of OIVI [17] [18] [19] . One patient of the six reported by Richards et al 6 had been given pregabalin 75 mg bd and had received three doses prior to recognition of OIVI.
It may also be reasonable to look at the way in which buprenorphine is prescribed for acute pain. For example, it is suggested that initial doses of pure agonist immediaterelease (IR) opioids such as morphine, oxycodone and fentanyl, should be based on the age of an adult patient 20 . The reasons behind the age-related decrease in opioid requirement appear to be due mainly to differences in drug pharmacodynamics rather than pharmacokinetic factors 9 . While it is not known whether this applies to buprenorphine, it may be reasonable to think about using lower doses in older patients, at least initially, until the effect in each patient can be assessed. Richards et al 6 recommend "a 'start low go slow' approach with a low initial dose and careful titration" in this patient group.
Prescribed dose interval may also be important. Many institutions allow two-hourly prn administration of IR morphine, oxycodone and fentanyl by SC, IM and oral routes 20 ; some institutions allow hourly prn. This is based on the premise that the peak effects (both analgesia and side-effects) of IR opioids given by these routes are likely to be seen within an hour in most patients 9 . However, the peak effect of buprenorphine may take as long as 90 minutes even when given as an IV bolus dose 9 . The results of a study in healthy volunteers showed that peak depression of ventilation after IV administration of buprenorphine may occur even later-between 150 and 180 minutes 11 .
In Bullingham et al's 21 original work in postoperative patients given SL buprenorphine tablets, peak plasma concentrations (C max ) were seen at a mean of 150 minutes. However, one patient achieved a C max after 20 minutes while some patients had not achieved it by three hours. The authors therefore performed another study with measurements done at intervals up to ten hours. In this study, the mean C max for SL buprenorphine was 200 minutes (range 90-360 minutes) 22 . Peak effect may therefore similarly be delayed. It should also be noted that buprenorphine, given as an SL tablet, has a mean half-life of 28 hours, which is much longer than IR morphine, oxycodone and fentanyl 9 . Prescribed dose intervals for SL buprenorphine must take this into account in order to minimise the potential risk of 'dose stacking'. If another dose of the drug is given well before the peak effect (or peak side-effect) of the previous dose has been seen, the risk of OIVI may increase. The dose intervals prescribed for prn administration of SL buprenorphine may therefore need to be longer than pure agonist IR opioids such as fentanyl and oxycodone. A dose interval of six-to eight-hourly has been suggested for buprenorphine given by IM injection or sublingually (200-400 µg) 20 . Richards et al 6 reported that some patients in their case series received a number of doses in a relatively short time.
Compared with OIVI resulting from pure agonist IR opioids, reversal of buprenorphine-induced OIVI with naloxone may require higher doses and/or a longer duration of treatment because of the slow dissociation kinetics of buprenorphine from mu-opioid receptors 23 . This was also noted by Richards et al 6 in the five of their patients given naloxone.
Measurement of a patient's adequacy of ventilation (e.g. using continuous end-tidal CO 2 levels) is the most accurate measure of OIVI, and it has been suggested such monitoring should be mandatory in all patients given an opioid for management of their acute pain 14, 15, 24 . However, this is not yet feasible in most institutions. Other surrogate indicators must therefore be employed.
Respiratory rate is the surrogate measure most commonly used to detect early-onset OIVI; OIVI is usually defined as a respiratory rate of less than ten, or less commonly, eight breaths per minute, even though there is little good evidence underlying the assumptions for these specific rates. However, it is known to be an unreliable indicator of OIVI and a respiratory rate within the 'normal' range may co-exist with high PaCO 2 levels 25 . This was first recognised by Ready et al in their 1988 publication reporting on the results from the first year of their Acute Pain Service 26 . Four patients developed significant OIVI following administration of epidural morphine. Two were said to be markedly sedated and their highest PaCO 2 levels were 63 and 66 mmHg. The other two were unconscious with PaCO 2 levels of 85 and 95 mmHg. No patient had a respiratory rate of less than eight breaths per minute and the lowest respiratory rate recorded in the patient with a PaCO 2 of 95 mmHg was twelve breaths per minute. The patient with the highest PaCO 2 (106 mmHg) in the series published by Richards et al 6 still had a respiratory rate of nine breaths per minute.
Less often, oxygen saturation is used as the surrogate measure of OIVI, but it lacks sensitivity when supplemental oxygen is administered, and there are also many reasons other than opioids for hypoxaemia in the acute setting 25 . The ECRI Institute, formerly the Emergency Care Research Institute, no longer recommends the purchase of pulse oximeters for this purpose 24 .
All the patients in the cases reported by Richards et al 6 were noticed to have had a deterioration in their Glasgow Coma Scale scores or level of consciousness prior to the diagnosis of OIVI, and in some a progressive deterioration had been noticed over some hours. Therefore, the authors suggested that "Reduced conscious state (increasing sedation) is an additional consideration when monitoring for respiratory depression in patients receiving buprenorphine". However, sedation is not just a feature of buprenorphinerelated OIVI. In the closed claims study by Lee et al 15 , increasing somnolence prior to the OIVI event was reported in 62% of the cases. Therefore, regular assessment of a patient's level of sedation as an indicator of impending OIVI, using sedation scores that reflect a progressive decrease in level of consciousness, should be part of the monitoring required for every patient given an opioid for management of their acute pain 25 . This has now also been recommended by Lee et al 15 , Overdyk at al 14 and the ECRI Institute 24 . It is also important to develop appropriate triggers for early intervention based on the patient's sedation level.
One of the patients in the series reported by Richards et al 6 was also prescribed a transdermal buprenorphine patch. The popularity of these patches for the treatment of acute pain appears to be increasing 7, 8 . However, it should be noted that steady state plasma concentrations are only reached on the third day after application 9 , meaning that rapid titration to analgesic effect in acute pain is not possible with the patch alone, and IR opioids may also be required, increasing the risk of OIVI.
In summary, the case reports by Richards et al 6 provide an excellent insight into the risks of OIVI with buprenorphine and the potential difficulties with its reversal should naloxone be required. The authors highlight factors that may increase the risk of OIVI, how patients should be monitored when given an opioid, and why dose stacking can occur when repeat doses of SL buprenorphine are given or concurrent opioids administered by another route. The authors recommend caution in the use of SL buprenorphine in elderly opioid-naïve patients "especially if they have comorbidities or are taking other central nervous system depressants". However, caution is probably also needed when prescribing this medication to any patient. Regardless of the opioid used for acute pain management, patients will be at higher risk of OIVI if the differences in time to peak effect of all opioids via different routes of administration are not taken into account; if the need to avoid preventable risk factors is not better understood; and if the level of sedation is not routinely measured on a regular basis. In addition, appropriate actions must be triggered if the patient becomes oversedated.
Finally, some may believe that buprenorphine has a lower misuse potential compared with other full agonist opioids. Unfortunately, not long after buprenorphine was introduced, reports of abuse of buprenorphine were published. O'Connor et al 27 noted that, as early as 1983, there were reports of abuse of both the SL and injectable formulations from Ireland, England, Scotland, Australia and New Zealand, and concluded that "this is a drug of high abuse potential". Fortunately, a recent analysis of calls to the National Poison Data System in the United States indicated that the rates of intentional abuse for transdermal buprenorphine patches (rates were adjusted using number of prescriptions to reflect availability in the community) were significantly lower than for slow-release formulations of morphine and oxycodone, fentanyl patches, and methadone 28 . But once again, this rate was not zero.
